Aurobindo Pharma

Complex Generics And Biosimilars Will Fuel Secular Demand

AnalystHighTarget

Not Invested

Community Contributor

Published

20 Jun 25

Updated

12 Dec 25

Views

n/a

AnalystHighTarget's Fair Value

n/a

-2.9%

1.2%

-2.9%

1.2%

You can edit this narrative until Dec 13 5:05 PM. Then, changes will post as Updates.

Author's Valuation

₹1.64k28.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on 12 Dec 25

Fair value Decreased 4.87%

AUROPHARMA: Margin Expansion And Pipeline Execution Will Drive Upside Potential

Analysts have trimmed their fair value estimate for Aurobindo Pharma from ₹1,724 to ₹1,640, reflecting a modestly higher discount rate and lower future P E multiple, even as they factor in stronger revenue growth and expanding profit margins. Analyst Commentary Bullish analysts acknowledge the trimmed fair value but continue to view Aurobindo Pharma as well positioned to compound earnings, supported by a healthier product mix, scale benefits, and operating leverage in key export markets.

AnalystHighTarget Fair Value

₹1.64k

28.2% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

5.20%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.76%

Calculation

₹68.16b

Earnings '28

20.01x

PE Ratio '28

₹1.36t

Market Cap '28

₹1.36t

Market Cap '28

580.19m

No. shares '28

₹2.35k

Share Price '28

₹2.35k Share Price '28

Discounted to 2025 @ 12.76% p.a.

₹1.64k

Fair Value '25